Revance Therapeutics (RVNC) Tops Q4 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.93), $0.09 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.27 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Kotak Starts Mazagon Dock Shipbuilders (MAZDOCKS:IN) at Sell (4)
• Chubb Corporation (CB) PT Raised to $337 at Cantor Fitzgerald: 'Remains Well-Positioned'